Avant Diagnostics, Inc. (AVDX) Targets Corporate Transparency with Launch of New Website
Avant Diagnostics, Inc. (OTC: AVDX) is on a mission to maximize its levels of corporate transparency for the benefit of its customers and investors. Late last week, the company took a significant step toward realizing this goal when it unveiled its new website. The new site utilizes a number of design features aimed at making browsing both streamlined and informative for Avant’s current and potential customers and investors.
The site’s investor relations section, in particular, received a considerable upgrade, incorporating helpful features such as immediate posting of press releases and automated posting of SEC filings, XBRL data, Insider Section 16 filings and financial statements. Additionally, the company has incorporated CEO interviews and media coverage, corporate videos and an up-to-date frequently asked questions section in order to more adequately inform visitors about Avant’s latest advances.
“A significant part of Avant’s mission is presenting those interested in the company with the information they want in the quickest and most organized way,” Gregg Linn, president and chief executive officer of Avant, stated in a news release. “We believe our new website advances this goal by presenting our range of services and activities in an attractive and easy-to-access format.”
In the months to come, Avant in strategically positioned to continue the development of its pre-symptomatic ovarian cancer screening test, OvaDx®. Leveraging more than 10 years of research and development and a strong intellectual property portfolio, the company is seeking to reduce the costs associated with ovarian cancer detection while helping medical providers avoid costly late stage disease treatments.
According to data from the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more fatalities than any other cancer of the female reproduction system. However, early detection can play a major role in improving the survivability of this dangerous disease. According to the National Cancer Institute, ovarian cancer cases discovered in stage I development present patients with a five-year relative survival rate in excess of 92 percent. Despite the benefits of early detection, only about 15 percent of ovarian cancer cases are currently diagnosed at stage one.
Through the development of OvaDx, Avant is seeking to provide a more effective option for detecting early stage ovarian cancer. The microarray-based diagnostic test, which, upon FDA approval, is expected to be offered as an elective test for women with elevated risk of ovarian cancer, has been shown to detect stage IA disease markers with approximately 80 percent sensitivity and 100 percent specificity.
For more information, visit www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Avant Diagnostics, Inc. (OTC: AVDX) is on a mission to maximize its levels of corporate transparency for the benefit of its customers and investors. Late last week, the company took a significant step toward realizing this goal when it unveiled its new website. The new site utilizes a number of design features aimed at making browsing both streamlined and informative for Avant’s current and potential customers and investors.
The site’s investor relations section, in particular, received a considerable upgrade, incorporating helpful features such as immediate posting of press releases and automated posting of SEC filings, XBRL data, Insider Section 16 filings and financial statements. Additionally, the company has incorporated CEO interviews and media coverage, corporate videos and an up-to-date frequently asked questions section in order to more adequately inform visitors about Avant’s latest advances.
“A significant part of Avant’s mission is presenting those interested in the company with the information they want in the quickest and most organized way,” Gregg Linn, president and chief executive officer of Avant, stated in a news release. “We believe our new website advances this goal by presenting our range of services and activities in an attractive and easy-to-access format.”
In the months to come, Avant in strategically positioned to continue the development of its pre-symptomatic ovarian cancer screening test, OvaDx®. Leveraging more than 10 years of research and development and a strong intellectual property portfolio, the company is seeking to reduce the costs associated with ovarian cancer detection while helping medical providers avoid costly late stage disease treatments.
According to data from the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more fatalities than any other cancer of the female reproduction system. However, early detection can play a major role in improving the survivability of this dangerous disease. According to the National Cancer Institute, ovarian cancer cases discovered in stage I development present patients with a five-year relative survival rate in excess of 92 percent. Despite the benefits of early detection, only about 15 percent of ovarian cancer cases are currently diagnosed at stage one.
Through the development of OvaDx, Avant is seeking to provide a more effective option for detecting early stage ovarian cancer. The microarray-based diagnostic test, which, upon FDA approval, is expected to be offered as an elective test for women with elevated risk of ovarian cancer, has been shown to detect stage IA disease markers with approximately 80 percent sensitivity and 100 percent specificity.
For more information, visit www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
